Mazieres, J., Paik, P. K., Garassino, M. C., Le, X., Sakai, H., Veillon, R., . . . Thomas, M. (2023). Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: Long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA oncology, 9(9), . https://doi.org/10.1001/jamaoncol.2023.1962
Chicago-Zitierstil (17. Ausg.)Mazieres, Julien, et al. "Tepotinib Treatment in Patients with MET Exon 14-skipping Non-small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial." JAMA Oncology 9, no. 9 (2023). https://doi.org/10.1001/jamaoncol.2023.1962.
MLA-Zitierstil (9. Ausg.)Mazieres, Julien, et al. "Tepotinib Treatment in Patients with MET Exon 14-skipping Non-small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial." JAMA Oncology, vol. 9, no. 9, 2023, https://doi.org/10.1001/jamaoncol.2023.1962.